A venture capital firm founded in January 2018 is actively seeking new investments. The founding partner has invested in over 20 early-stage companies through his previous investment firm with biotech comprising the majority of the investments. The firm focuses on early-stage diagnostics, life science research tools, and biotech-related companies. The firm’s target initial investment size is $500K-$1M, and the firm has made one investment so far. The firm prefers to act as the co-investor with other types of investors such as strategic partners. The firm invests in companies that are based in the US. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is currently seeking to invest in early-stage diagnostics, life science research tools, and biotech-related companies. The firm will invest in a limited number of therapeutic opportunities. The firm also has interests in other technology fields. The firm is opportunistic in terms of subsectors and indications. The firm will consider investing in companies that have strong intellectual property protection and provide barriers to competitive entry. The firm also seeks companies with potential large addressable markets, which typically have the potential to generate at least $100M of annual revenues.

The firm seeks a reliable and experienced management team that can bring the concept to market. The firm may take a board seat in applicable cases. The firm aims fundraising CEOs that are driven to deliver exceptional investment returns to both investors and management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm headquartered in Tokyo, Japan with an additional office in the USA is focused on R&D and venture funding of new companies. Typical allocation sizes range from $0.2M-$2M, and may be structured as research funds, equity, or convertible loans depending on the phase of development. The firm will consider companies at all stages from concept to OTM, with OTM products being candidates for M&A and distribution agreements. Investments are focused on medical technology and diagnostics companies.

The firm is interested in medical technology and diagnostics companies across indications, but has a current focus in cardiovascular and regenerative indication areas.

The firm may or may not seek a board seat on companies they invest in. They are open to working with all management teams, and view deals globally.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investor group based out of New York, USA with financial backing from China is interested in looking at US-based opportunities that they believe will translate well to the Chinese market. These opportunities do not need to already have traction in China since the firm hopes to be a Chinese partner to help them access and succeed in these markets in addition to being an investor. The firm expects to make 20-50 investments this year and is prioritizing investments in the $10-50 Million USD range, but is also willing to look at earlier stage opportunities.

The firm is interested in medical devices. Specifically, medical devices related to senior care, health planning, data collection, data analysis and management, 24/7 patient monitoring systems, and devices that can help facilitate conversations between patients and caregivers. Companies they’ve worked with and still have interest for include: laser treatment devices for arthritis, devices for rehabilitation, and devices for surgery. While a lot of their interest areas overlap with Healthcare IT companies, they only have a slight interest in this area as they believe the Chinese markets are already flooded in that area. For device companies, the firm prefers that they already have FDA approval, but are willing to look at companies who are close to completing FDA pivotal trials as well.

The firm prefers companies that are ideally already revenue generating, but they are also willing to look at companies that are near revenue generation. The firm wants to work with companies who are interested in accessing the Chinese market and are willing to form a joint venture with the firm in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Bay area-based corporate VC fund is independently managed in a strategic partnership with their corporate. The firm invests in early-stage disruptive life science tools, therapeutics, and diagnostic companies. Typical allocations range from $2-10 million initially in a Series A or B round and can be up to $15-20 million over the life span of the company. The firm seeks to syndicate with other leading institutional and strategic investors. The firm expects to make 4-5 new investments over the next 12 months and considers opportunities globally with a focus in the US.

The firm is interested in areas where its expertise and special relationship with the parent company can add value. The firm focuses on applications of genomics including sequencing, assay development, agriculture and environmental science, industrial biotech, digital health, public safety and personal wellness, proteomics and other ‘omics’ areas. The firm prefers pre-revenue companies that have achieved proof-of-concept.

The firm seeks to work with experienced management teams with sector expertise. The firm’s team members have decades of entrepreneurial experience in genomics and may request a board seat depending on the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A East Coast region-based large pharmaceutical specializes in the development of treatments for ultra-orphan diseases (diseases with under 20,000 patients in the USA or EU), and is seeking to in-license novel therapeutics and platforms in this space.

The firm is focused on serving patients and families affected by rare diseases. The firm focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An evergreen private equity firm launched by a French family office is headquartered in Paris with additional offices in USA and China. The firm was created with an aim to invest in high growth opportunities in healthcare and multiple other sectors outside of retail. The firm typically makes minority investments of US$2-10 million in Series A and B rounds (either as lead or co-investor in a round). The firm is currently seeking new opportunities in France, United States, and China.

Within healthcare, the firm is interested in digital health applications that improves quality or efficiency of care, such as telemedicine, patient-doctor interface workforce coordination, and analytics software. In particular, the firm’s USA offices are focused on agtech businesses, such as agriculture tech and food. The firm prefers enterprise solutions, but can also consider consumer products. The firm is not interested in insurance, cosmetics, nutraceutical or well-being products. For hardware devices to be considered, it must have a strong software/data component as its core technology. The firm is agnostic to disease areas and is currently most interested in elderly care. The firm prefers to work with growth-stage companies that are revenue-generating.

The firm is looking for companies formed by a team of founders with expertise in the medical, technology, and sales and marketing sectors. One-person companies are less likely to be considered. The firm seeks teams that are able to work across cultures and grow into international markets. The firm is a long-term investor that works closely with its portfolio companies and strives to create a sharing culture together.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture capital arm of a global pharmaceutical invests in early stage healthcare companies of strategic interest to the parent pharmaceutical (typically seed or series A). The firm has a global mandate and is currently seeking new equity investment opportunities.

As a strategic investor, the firm makes direct equity investments in innovative start-ups aligned with the pharmaceutical’s areas of strategic focus. Among these areas are rare diseases, vaccines, digital health solutions, etc. The firm seeks products that are in preclinical or early clinical development and that have proof-of-concept data.

The firm has a flexible funding structure and is able to lead and co-lead rounds as well as co-invest with top tier life science investors. The firm seeks to be a long-term investor with board responsibilities either as a full seat or as an observer.

In addition to equity financing, the firm provides strategic and technical input to portfolio companies through the established expertise of their teams. The success of the firm is driven by the ability to invest in areas where the fund can provide a unique voice and insight, active portfolio company engagement and the facilitation of future strategic collaborations with the parent pharmaceutical.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.